EUVIMEDOpdag EUVIMED
Multizentrische Studie

Multicenter experience with andexanet alfa for refractory pericardial bleeding during catheter ablation of atrial fibrillation

Tarek Zghaib, John D Allison, Christopher Barrett iD, Jeffrey Arkles iD, Benjamin D'Souza, Jeffrey Luebbert, Fermin Garcia, E Kevin Heist, Wendy Tzou iD, David Callans, Francis E Marchlinski, David S Frankel iD

Journal of Cardiovascular Electrophysiology · 2023

DOI: 10.1111/jce.15801 ↗

At a glance

Multizentrische Studie in Journal of Cardiovascular Electrophysiology, 2023. Written by Tarek Zghaib and 11 co-authors. Institution: Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Major MEDLINE topics: Atrial Fibrillation, Thromboembolism, Catheter Ablation. Cited 1 times so far (Crossref); 11 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Introduction

Pericardial bleeding is a rare but life‐threatening complication of atrial fibrillation (AF) ablation. Patients taking uninterrupted oral anticoagulation (AC) may be at increased risk for refractory bleeding despite pericardiocentesis and administration of protamine. In such cases, andexanet alfa can be given to reverse rivaroxaban or apixaban. In this study, we aim to describe the rate of acute hemostasis and thromboembolic complications with andexanet for refractory pericardial bleeding during AF ablation. Methods and Results In this multicenter, case series, participating centers identified patients who received a dose of apixaban or rivaroxaban within 24 h of AF ablation, developed refractory pericardial bleeding during the procedure despite pericardiocentesis and administration of protamine and received andexanet. Eleven patients met inclusion criteria, with mean age of 73.5 ± 5.3 years and median CHA 2 DS 2 ‐VASc score 4 [3–5]. All patients received protamine and pericardiocentesis, and 9 (82%) received blood products. All patients received a bolus of andexanet followed, in all but one, by a 2‐h infusion. Acute hemostasis was achieved in eight patients (73%) while three required emergent surgery. One patient (9%) experienced acute ST‐elevation myocardial infarction after receiving andexanet. Therapeutic AC was restarted after a mean of 2.2 ± 1.9 days and oral AC was restarted after a mean of 2.9 ± 1.6 days, with no recurrent bleeding.

Conclusion

In patients on uninterrupted apixaban or rivaroxaban, who develop refractory pericardial bleeding during AF ablation, andexanet can achieve hemostasis thereby avoiding the need for emergent surgery. However, there is a risk of thromboembolism following administration.

Subjects

MeSH terms (MEDLINE)

Atrial FibrillationThromboembolismCatheter AblationHumansAgedRivaroxabanFactor Xa InhibitorsHemorrhageProtaminesAnticoagulantsRecombinant ProteinsFactor Xa

Author keywords

andexanet alfaatrial fibrillationcardiac tamponadecatheter ablationdirect oral anticoagulantpericardial effusion

Substances

RivaroxabanFactor Xa InhibitorsProtaminesAnticoagulantsPRT064445Recombinant ProteinsFactor Xa

Authors and institutions

  • Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Cardiac Arrhythmia Unit, Heart Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Division of Cardiovascular Medicine, Section of Electrophysiology, School of Medicine, University of Colorado, Aurora, Colorado, USA.

ORCID profiles: Christopher Barrett, Jeffrey Arkles, Wendy Tzou, David S Frankel

Cite

APA

Zghaib, T., Allison, J. D., Barrett, C., Arkles, J., D'Souza, B., Luebbert, J., Garcia, F., Heist, E. K., Tzou, W., Callans, D., Marchlinski, F. E., & Frankel, D. S. (2023). Multicenter experience with andexanet alfa for refractory pericardial bleeding during catheter ablation of atrial fibrillation. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.15801

Vancouver

Zghaib T, Allison JD, Barrett C, Arkles J, D'Souza B, Luebbert J, et al. Multicenter experience with andexanet alfa for refractory pericardial bleeding during catheter ablation of atrial fibrillation. Journal of Cardiovascular Electrophysiology. 2023. doi:10.1111/jce.15801

BibTeX
@article{Zghaib2023,
  author = {Zghaib, Tarek and Allison, John D and Barrett, Christopher and Arkles, Jeffrey and D'Souza, Benjamin and Luebbert, Jeffrey and Garcia, Fermin and Heist, E Kevin and Tzou, Wendy and Callans, David and Marchlinski, Francis E and Frankel, David S},
  title = {Multicenter experience with andexanet alfa for refractory pericardial bleeding during catheter ablation of atrial fibrillation},
  journal = {Journal of Cardiovascular Electrophysiology},
  year = {2023},
  doi = {10.1111/jce.15801}
}
Start for free →